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Abstract
Introduction. Chronic rhinosinusitis (CRS) affects 14% of the world population. The high motility group box 1 
(HMGB1) protein triggers inflammation, cell proliferation and cell survival through its receptor for advanced 
glycation end products (RAGE) upon release from stressed or necrotic cells. The aim of the study was to ana-
lyze the expression and function of HMGB1 and RAGE in CRS, providing more information about HMGB1 
signaling pathway in CRS, to determine its potential clinical significance. 
Material and methods. Thirty-seven patients with CRS and 26 normal controls (NC) were enrolled in this study. 
Classification of disease severity using the SNOT-20 questionnaire, nasal endoscopy, CT scan, assessment of 
allergy status, microbiological and cytological analysis was performed in patients. Fresh sinus mucosa samples 
were obtained and analyzed by immunohistochemistry for HMGB1 and RAGE expression in epithelial cells. 
ELISA assay was performed to evaluate the concentration of HMGB1 in the patients’ sera.
Results. No differences were found in HMGB1 immunoexpression between CRS patients and NC, however there 
was a highly significant difference in RAGE immunoexpression between both groups. There was a correlation 
between RAGE expression and number of tissue-infiltrating lymphocytes. Further, RAGE expression positively 
correlated with disease severity and a positive history for allergies. 
Conclusions. Interaction of HMGB1 and RAGE might be relevant to CRS pathomechanisms leading to sinus 
mucosa hyperproliferation. CRS pathogenesis might be especially related to the RAGE overexpression correlated 
with disease severity and allergy. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 1, 70–78)
Key words: rhinosinusitis; chronic inflammation; HMGB1; RAGE; IHC; serum
Introduction
The immune system has evolved to respond to exo-
genous components of microbes through pathogen-as-
sociated molecular patterns (PAMPs) detected by 
pattern-recognition receptors (PRRs), and also to 
endogenous danger signals, or damage-associated mo-
lecular patterns (DAMPs). DAMPS are released by 
dying or necrotic cells and contribute to inflammation. 
High motility group box 1 protein (HMGB1) is a mul-
tifunctional nuclear protein and one of the well-known 
members of the DAMP family [1]. It is present within 
the nuclei of almost all eukaryotic cells and functions 
as a DNA chaperone that stabilizes nucleosome 
formation and promotes access to transcriptional 
factors that target specific genes. Upon its release 
from stressed or necrotic cells, HMGB1 acts as an ex-
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tracellular trigger of inflammation, cell proliferation, 
migration and survival, mainly through interactions 
with its receptor for advanced glycation end products 
(RAGE) [2]. RAGE ligands are either released during 
cellular stress (S100 proteins, HMGB1, nucleic acids), 
or generated during prolonged hyperglycemia and in-
flammation (AGE, amyloid) [3]. Due to an enhanced 
level of RAGE ligands in chronic disorders, this 
receptor is hypothesized to have a causative effect in 
a range of inflammatory diseases [3–5]. Though RAGE 
was first identified as the receptor for HMGB1, subse-
quently, toll-like receptors 2 (TLR2) and TLR4 have 
also been identified to be involved in HMGB1 sig-
naling [6]. These interactions trigger activation of key 
signaling pathways involved in the regulation of innate 
and adaptive immunity [7], polarizing the immune re-
sponse towards Th1 or Th2 and secretion of different 
cytokines. Chavakis et al. demonstrated that RAGE 
can directly regulate leukocyte recruitment by serv-
ing as a counter-receptor for b2-integrin Mac-1 [8]. 
RAGE activation plays a role in various diseases, 
including sepsis, rheumatoid arthritis, diabetic ne-
phropathy, atherosclerosis, neurological diseases 
and cancer [9–13]. RAGE receptor exists in the cells 
in two different forms: mRAGE (membrane bound, 
full-length molecule containing transmembrane and 
cytoplasmic domains) and sRAGE (soluble, shorter 
form). sRAGE derived via alternative mRNA splicing 
is known as esRAGE (endogenous secretory RAGE’ 
or RAGE_v1), whereas sRAGE derived from the 
proteolytic cleavage of mRAGE is referred to as 
cleaved RAGE (cRAGE). The soluble sRAGE form 
is present in the in the extracellular space and can bind 
RAGE ligands in the circulation [14, 15]. 
Chronic rhinosinusitis (CRS) is one of the most 
common health concerns affecting 14% of the world’s 
population. The prevalence of CRS has increased 
over the last decade and has become a serious health 
problem. CRS is associated with significant low quality 
of life index, comparable to levels noticed in patients 
with life-risk illnesses such as chronic obstructive 
pulmonary disease or congestive heart failure [16]. 
Although a number of contributing factors are re-
cognized, the underlying cause and mechanism of 
this disease remain unknown, and definite curative 
treatment does not exist.
CRS comes in two different subtypes, namely CRS 
without polyps (CRSsNP) and CRS with polyps (CR-
SwNP). CRSwNP is diagnosed when nasal polyps are 
visible at an appropriate nasal endoscopic examina-
tion. Otherwise, the disease is classified to CRSsNP. 
In the European position paper on rhinosinusitis and 
nasal polyps (EPOS 2012) [17], the current pathogen-
esis of these two CRS subtypes has been discussed. 
Current research focuses on epithelial/immune cell 
interactions, the biofilm hypothesis and the superan- 
tigen hypothesis. CRS may be associated with other 
diseases, especially allergies, asthma or aspirin-exacer-
bated respiratory disease (AERD). The standard 
diagnostic procedures include medical history, nasal 
endoscopy, CT-scans (computed tomography) of 
the paranasal sinus, and allergy testing for common 
inhalant allergens. The American Academy of Oto-
laryngology has recommended the Lund and Mackay 
system for CT staging of CRS [18]. The choice of CRS 
therapy depends upon symptom intensity and includes 
topical steroids, antibiotics and/or surgery [19, 20].
To the best of our knowledge, there is currently no 
data available on both HMGB1 and RAGE expres-
sion and function in CRS pathogenesis. Few authors 
assessed HMGB1 expression in CRS patients, how-
ever, RAGE expression in correlation with HMGB1 in 
tissue has yet not been studied [21–23]. Furthermore, 
in one paper HMGB1 expression was assessed mainly 
in the inflammatory infiltrates (or polyp tissue) [24] 
and not in epithelial cells. There is emerging interest 
in the role of molecules that bind HMGB1, including 
RAGE, in CRS. We assumed that HMGB1-RAGE 
signaling pathway may contribute to the CRS patho-
mechanisms. To test our hypothesis, we investigated 
expression of HMGB1 in the whole tissue including 
the epithelial cells and the stroma of sinonasal muco-
sa obtained from CRS patients vs. epithelial cells of 
nasal mucosa of normal controls. Given the fact that 
HMGB1-RAGE interactions are known to promote 
inflammation in various pathologies, we hypothesized 
that these interactions could also occur and play 
a critical role in CRS. 
Material and methods
Patients and tissue collection. Fresh sinus mucosa samples 
were obtained during surgery of the osteomeatal complex 
in 37 individuals diagnosed with CRS without nasal polyps 
(CRS). Based on EPOS 2012 classification [17], the presence 
of clinical and radiological evidence of chronic rhinosinus-
itis and absence of polyps in nasal endoscopy examination 
was required for entry into this study. Table 1 summarizes 
characteristics of the subjects included in this study. The 
group of CRS patients included 19 males and 18 females 
patients (median age 42 years, range 15–71 years). The 
group of normal healthy controls (NC) comprised 18 men 
and 8 women (median age 40 years; range 16–69 years). The 
control subjects had nasal structural deformities, without 
clinical and radiological evidence of chronic rhinosinusitis. 
Control sinus mucosa (C-SM) included non-inflammatory 
changed normal mucosa from osteomeatal complex region. 
The study was approved by the Local Ethics Committee, 
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Warsaw Medical University, Poland (KB 103/2012) and was 
compliant with the Helsinki Declaration. All participants 
signed an informed consent.
The classification of disease severity was performed 
using the SNOT-20 questionnaire (Sino-Nasal Outcome 
Test), nasal endoscopy and CT scan graded by Lund-Mackay 
scoring system [18, 25]. We also recorded a number of sinus 
surgeries performed in CRS patients reflecting the recalci-
trant sinus disease and intensity of CRS.
Allergy status. Allergy status was assessed based on the 
patient’s history, a skin prick test and total IgE levels in 
patient’s blood samples. NSAIDs allergy (nonsteroidal 
anti-inflammatory drugs allergy) and asthma were noted 
based on spirometry and medical anamnesis. 
Microbiology. To determine the composition of sinonasal 
cultures, the middle meatus sample collection was per-
formed in each patient under endoscopic control. Nasal 
swabbing from middle nasal meatus followed by agar culture 
identified the bacterial species present in the nasal cavity.
Cytology. To determine the population of inflammatory cells 
in the nasal cavity, cytology samples were taken under the 
middle turbinate. The cells were smeared on glass slides, 
fixed with alcohol, stained with hematoxylin and eosin 
(H & E) and evaluated under the light microscope. In the 
evaluation of the cytograms of each patient it was found that 
they could be classified to one of the six types of cytograms, 
previously described by Canakcioglu et al. [26]. 
Immunohistochemistry. Formalin-fixed and paraffin-em-
bedded tissues sections were stained with H & E for light 
microscopy evaluation. The following primary antibodies 
were used for immunostaining of tissue sections: rabbit 
polyclonal anti-human HMGB1 diluted with Dako Antibody 
Diluent (1:1,000, Abcam, Cambridge, UK), rabbit polyclonal 
anti-human RAGE (1:100, LifeSpan Bioscience Inc., Seattle, 
WA, USA) and isotype control IgG (Dako, Gdynia, Poland). 
Paraffin sections of sinus mucosal tissue or normal mucosa 
were stained as previously described [27]. After standard 
deparaffinization, the EnVision+ System (Dako) was used 
for staining according to the manufacturer’s instructions. 
In short, after an overnight incubation with the primary 
antibodies (anti-human HMGB1, anti-human RAGE), 
sections were incubated with labeled polymer-horseradish 
peroxidase (HRP) anti-rabbit antibody and then with 3,3’-di-
aminobenzidine (Dako). To eliminate nonspecific binding 
sections were incubated with a serum-free protein blocker 
before adding the primary antibodies. Sections were coun-
terstained with Meyer’s hematoxylin and mounted in DPX 
(POCH, Gliwice, Poland). Slides were evaluated under the 
light microscope at total magnification × 400 (Primo Star 
microscope, Carl Zeiss, Wetzlar, Germany). For digital 
image analysis, the software AnalySIS^B (Camera Olypmus 
DP12, Melville, NY, USA) was used. All stained sections were 
analyzed and scored by two independent investigators (M.J.S. 
and K.D.) to avoid bias, and the two scores were averaged and 
recorded. The sections were scored according to the % of rhi-
nosinusitis tissue staining (‘positivity’) (< 25% = 0; 25–75% 
= 1; and > 75% = 2). The level of staining intensity was re-
corded as none = 0, weak = 1, moderate = 2, or strong = 3. 
As a positive control for HMGB1 and RAGE expression, 
sections of intestine and kidney were used, respectively.
Measurement of serum concentration of HMGB1. To eval-
uate the level of HMGB1 in the patients’ sera, HMGB1 
ELISA kit (U.S. Customers antibodies-online Inc, Atlan-
ta, GA, USA) was used according to the manufacturers’ 
instructions.
Statistical analysis. Data were summarized by descriptive 
statistics (Statistica 10.0, Statsoft, Cracow, Poland). Fisher’s 
exact tests were used to determine if there was a difference 
in HMGB1 and RAGE expression among tissue types. 
Adjustments to p-values were made using the Bonferroni 
step-down procedure. The ANOVA Kruskall-Wallis test was 
used to evaluate differences between groups.
Table 1. Clinicopathological characteristics of chronic 
rhinosinusitis (CRS) patients and control group patientsa 
included in this study
Characteristics Controls 
n = 26
CRS
n = 37
Sex
   Male
   Female
18
8
19
18
Age
   Range
   Median
16–69
40
15–71
42
Allergy 2 10
Asthma 0 1
NSAIDsb allergy 2 0
Average CT Lund-Mackay  
scores
0.8 ± 0.4 4.8 ± 0.6
Average SNOT scores 21.5 ± 15.4 23.6 ± 19.5
Serum concentration  
of IgE [IU/mL]
.60 ± 8.8 2.156 ± 206.7
Positive microbiology findings 25% 34%
Values present mean ± standard deviation (SD). aThe patients inclu-
ded in the study received no oral steroid treatment for 2 months prior 
to surgery; bNSAIDs — nonsteroidal anti-inflammatory drugs
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Results
Cytology
In 23 of the CRS patients a neutrophil cytogram was 
noticed, in 7 an injury cytograms, in 5 an eosinophil cy-
tograms, in 1 a normal and in 1 a secretory cytograms. 
The control group showed normal nasal cytology in 
14 cases, neutrophil and eosinophil cytograms in 
4 cases and injure or secretory cytograms in 2 cases 
(Figure 1A2, 1A4).
HMGB1 immunoexpression in tissues
HMGB1 was detected in all tissues of normal controls 
and CRS patients. HMGB1 was localized in the nu-
clei and cytoplasm and in all cases staining intensity 
was evaluated as moderate or strong (Figure 1B1–4). 
We did not find statistically significant differences 
between NC vs. CRS in terms of HMGB1 immuno-
reactivity in the epithelial cells of sinonasal mucosa 
(Figure 1C; the epithelium lining marked with arrows 
and the stroma of sinus mucosa marked with stars).
No correlation was found between HMGB1 
expression and disease severity evaluated based on 
SNOT, nasal endoscopy examination, CT scan and 
a number of surgery. Furthermore, we did not find 
any significant differences in the patients’ cohort of 
HMGB1 expression and either the allergy or micro-
biological evaluation.
RAGE expression in tissues
RAGE was present in the cytoplasm of epithelial cells 
and inflammatory infiltrates. In CRS patients RAGE 
was detected in 94% of cases and its staining intensity 
ranged from weak to strong. RAGE was observed in 
40% of NC, however, its expression was weak (Figu-
re 1B5–8). Differences in RAGE expression between 
CRS and NC were highly significant (p < 0.00005) 
(Figure 1D). In the CRS tissue, a moderate to large 
number of RAGE-immunopositive inflammatory cells 
were observed (data not shown). 
RAGE immunoexpression positively  
correlates with disease severity
We observed significant differences in RAGE intensi-
ty and positivity depending on CT scan results (graded 
by the Lund-Mackay scoring system) in the CRS cohort 
(Figure 2). Staining intensity and positivity were stron-
ger in patients with a higher CT score reflecting more 
extensive inflammatory changes in sinuses (p = 0.0024, 
p = 0.0163, respectively). No significant differences 
in RAGE expression and severity of symptoms using 
the SNOT-20 questionnaire, or the number of pre-
viously performed surgeries in CRS patients or nasal 
endoscopy results were found. 
RAGE immunoexpression correlates  
with disease etiology
We observed significantly stronger RAGE positivity 
in the sinus mucosa of patients with higher serum 
IgE values, who suffered from allergy, compared 
to patients with negative history for allergies (Fi- 
gure 3A, B). We did not observe any correlation be-
tween RAGE expression, asthma or NSAIDs allergy. In 
this study, the microbiological content of the nasal cav-
ity was associated with RAGE expression (p = 0.007) 
(Figure 3C) but there was no differences in the me-
dian value of RAGE expression and the presence of 
specific microbes.
Serum concentrations of HMGB1
We did not find statistical significant differences be-
tween NC (28 ± 18 ng/mL, mean and SD) vs. CRS 
(mean 33 ± 15 ng/mL) in terms of the HMGB1 levels 
in patients’ sera. 
Discussion
Emerging data indicate that chronic inflammation is 
associated with the CRS development and progres-
sion. A complex set of innate and adaptive immune 
pathways are active at the mucosal surfaces both 
constitutively and in response to specific antigens. 
Overactivity or dysregulation of mucosal immune 
mechanisms could lead to persistent inflammation. To 
the best of our knowledge, expression and function of 
HMGB1-RAGE in mucosal immunity of the sinonasal 
tract has yet not been investigated. It is known that 
biofilm persistence was suggested to correlate with 
epithelial damage, subepithelial inflammatory cell 
infiltration, and tumor necrosis factor alpha (TNF-a) 
receptor expression in CRS [28]. This might result in 
apoptosis or hypoxia and necrotic cell death within 
the CRS tissue, followed by the release of HMGB1. It 
is likely that HMGB1 triggers paracrine activation of 
RAGE expressed in the CRS tissue but not (or only 
weakly) in normal mucosa. 
Current evidences indicate that HMGB1 plays 
a pivotal role in the activation of innate immunity 
followed by increased cytokine production, develop-
ment of inflammation and adaptive immune response 
[21–24]. Most studies of HMGB1 expression and 
function are focused on immune cells and suggest 
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Figure 1. HMGB1 and RAGE expression in normal control (NC) and in chronic rhinosinusitis tissues (CRS). A. Hema-
toxylin and eosin (H & E) staining: A1, NC mucosa; A2, NC cytology taken from under the middle turbinate; A3, CRS 
mucosa; A4, CRS cytology taken from under the middle turbinate; B1–4. HMGB1 expression: B1, human colon (positive 
control); B2, NC tissue of human nasal mucosa; B3, CRS tissue; B4, human respiratory epithelium, negative control (no 
primary antibody); B5–8. RAGE expression: B5, in the human kidney (positive control); B6, NC tissue; B7, CRS tissue; 
B8, isotype negative control staining in CRS; C. Intensity of HMGB1 staining in both the epithelium lining (marked 
with arrows) and the stroma of sinus mucosa (marked with stars). Representative pictures are shown; D. Comparison of 
RAGE positivity and intensity between NC and CRS patients. The sections were scored according to the% of rhinosinusi-
tis tissue staining (POSITIVITY) (< 25% = 0; 25–75% = 1; and > 75% = 2). The level of staining intensity was recorded 
as none = 0, weak = 1, moderate = 2, or strong = 3) (as described in Material and Methods). Representative pictures 
are shown. Abbreviations: NC — normal control group; CRS — patients with chronic rhinosinusitis without nasal polyps; 
HMGB1 — high motility group box 1; RAGE — receptor for advanced glycation end products. Magnifications: A1 and 
A3 — × 100, all other microphotographs — × 400
A
B
C
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that enhancement of HMGB1 functions promotes 
inflammation. We investigated expression of HMGB1 
in the whole tissue including the epithelial cells and 
the stroma of sinonasal mucosa obtained from CRS 
patients and normal control subjects. Available data 
indicated HMGB1 expression mainly in the inflam-
matory infiltrates (especially eosinophilic ones), not in 
epithelial cells [21]. Moreover, significant differences 
in the HMGB1 protein level as well as the messenger 
RNA levels of HMGB1 were found between non-eo-
sinophilic CRSwNP and controls [29]. This observa-
tion is consistent with our findings. 
Our study is interesting especially for elaborating 
co-expression of HMGB1 and RAGE in CRS. Con-
sistent with the previous studies [21–24] we now con-
firm the expression of HMGB1 in CRS. In addition, 
we found that RAGE expression was significantly 
up-regulated in CRS compared to normal mucosal 
epithelium. In the microenvironment of CRS, RAGE/ 
/HMGB1 signaling might be, at least in part, responsi-
ble for the induction of inflammatory reactions which 
contribute to the disease development. 
To address this hypothesis, we evaluated by im-
munohistochemistry the co-expression of HMGB1 
and its multiligand receptor RAGE in cells of the 
sinonasal mucosa. Here, we report for the first time 
that HMGB1 and RAGE are co-expressed in CRS. 
Our findings are consistent with those of Ferhani et 
al. who found elevated RAGE level in the lung tissue 
of patients with chronic obstructive pulmonary disease 
(COPD) [30]. It was reported by Crombruggen et al. 
that RAGE was expressed in the human upper airways 
under normal physiological conditions [14]. In their 
CRSsNP tissue, the tissue levels of the soluble RAGE 
(sRAGE) protein fraction was significantly higher com-
pared to normal tissue, while conversely, the mRAGE 
(membrane-bound RAGE) levels were significantly 
lower compared to normal tissue. These authors hypo-
thesized that the decrease of mRAGE protein observed 
in pathologic conditions was likely to be mediated via the 
cleavage of mRAGE by deregulated metalloproteinase 
activity to form sRAGE that subsequently binds cellular 
and extracellular matrix components [14]. Since in our 
study we used antibody which recognized both mRAGE 
and sRAGE we were unable to distinguish precisely both 
forms of this receptor.
Furthermore, to explore the possibility of an au-
tocrine interaction between HMGB1 and RAGE in 
CRS and normal mucosa we performed immunohisto-
chemical analysis that detected HMGB1 expression in 
all CRSsNP sinus mucosa tissues and normal mucosa. 
However, we did not find any statistical significant 
difference between sinus mucosa tissues and normal 
mucosa in terms of HMGB1 localization or staining 
intensity. Some authors evaluated separately the 
expression of HMGB1 or RAGE so they could not 
assess their co-expression in human upper airways 
tissues [22, 23]. Based on the analyses of RAGE– 
–DNA complex structure, other authors claimed 
that HMGB1 is not essential for the RAGE–DNA 
binding event, as DNA can directly bind to RAGE in 
the absence of HMGB1 [31]. This observation could 
explain the differences between RAGE and HMGB1 
expression noticed in our study.
Taken together, current literature suggests that 
RAGE has both pro- and anti-inflammatory prop-
Figure 2. Association of RAGE expression with disease severity. A. RAGE positivity vs. CT scoring; B. RAGE intensity 
vs. CT scoring. Abbreviations as in the description of Figure 1. CT — computed tomography. Adjustments to p-values 
were made using the Bonferroni step-down procedure
BA
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erties, but because the RAGE pathway is regulated 
differently in different diseases, interpretation of 
RAGE activation can be biased. Chavakis et al. [8] 
demonstrated that RAGE can directly regulate leu- 
kocyte recruitment by serving as a counter-recep-
tor for b2-integrin Mac-1. Further, RAGE shed 
and eliminated from lungs and sinonasal tissue 
might lose its local regulatory function that is nece- 
ssary for normal immunologic homeostasis of the 
airways.
Since RAGE is involved in several inflammatory 
processes we wondered if there is any correlation 
between the RAGE expression and disease severity. 
To address this question, we analyzed the clinical 
relevance of RAGE and HMGB1 expression in CRS 
patients. We found that the level of RAGE expres-
sion correlated with disease severity. We observed 
significant differences in RAGE staining intensity 
and immunopositivity depending on CT scan results 
graded by the Lund-Mackay scoring system, IgE value, 
microbiological status, and allergy. Our data point at 
correlation of RAGE expression and higher CT score 
reflecting more extensive inflammatory changes in 
sinuses. Our findings prove that no correlation could 
be found between RAGE expression and disease 
severity measured by SNOT-20 questionnaire, nasal 
endoscopy and a number of previously performed 
surgeries in CRS patients. Surprisingly, cytology re-
sults, asthma or NSAIDs also did not affect RAGE 
expression. We also observed that a positive microbio-
logical status of the nasal cavity correlated with higher 
RAGE expression which is consistent with study of 
Crombruggen [14], however, in our study there was 
no evident correlation between specific microbes and 
RAGE expression. 
Based on our findings, we suggest that the HMGB1 
and RAGE interactions might play a role in recal-
citrant CRS and promote inflammatory mucosal 
changes. The association between RAGE expression 
and disease severity suggests that the HMGB1 and 
RAGE dysregulation may disturb the immune barrier 
function of the nasal mucosa. This may compromise 
the host defense, making the sinus mucosa more 
susceptible to antigenic insults, which could lead to 
chronic inflammation.
The potential pathogenic role of HMGB1 and 
RAGE in various inflammatory disorders is support-
ed by experimental studies which demonstrate that 
neutralizing or binding blocking HMGB1-RAGE 
signaling are effective in preventing chronic inflam-
mation [32–34]. Application of antibodies blocking 
HMGB1-RAGE could be also effective in CRS, 
enlarging the repertoire of potential therapeutic 
options for this disease. Treatment with selected 
anti-HMGB1-RAGE antibodies might attenuate 
persistent Th2-biased inflammation and thus immu-
nomodulate CRS.
Figure 3. Comparison of negative or positive RAGE 
expression in CRS patients in relation to the levels of IgE, 
presence of allergy and microbiological content of nasal 
swabs. A. RAGE positivity vs. serum IgE concentration 
(IU/mL); B. RAGE positivity vs. presence of allergy;  
C. RAGE intensity vs. nasal cavity swab culture
B
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C
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